Translational endpoints in fragile X syndrome

Neuroscience and Biobehavioral Reviews

Volumn 46, Issue P2, 2014, Pages 256-269

  de Esch, Celine E F ^a   Zeidler, Shimriet ^a   Willemsen, Rob ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

FMR1; Fmr1 KO mouse; Fragile X syndrome; Outcome measures; Therapy

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACAMPROSATE; ALFAXALONE; ARBACLOFEN; BACLOFEN; BASIMGLURANT; BIOLOGICAL MARKER; DONEPEZIL; FENOBAM; GANAXOLONE; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INITIATION FACTOR 4E; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; MAVOGLURANT; MEMANTINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; MEVINOLIN; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; NPL 2009; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P70; PROTEIN SERINE THREONINE KINASE; RILUZOLE; UNCLASSIFIED DRUG; VALPROIC ACID; FRAGILE X MENTAL RETARDATION PROTEIN; NOOTROPIC AGENT;

ABERRANT BEHAVIOR CHECKLIST COMMUNITY SCALR; ADHD RATING SCALE; AUTISM DIAGNOSTIC OBSERVATION SCALE; CHILDHOOD AUTISM RATING SCALE; CHILDREN YALE BROWN OBSESSIVE COMPULSIVE SCALE; CLINICAL EVALUATION OF LANGUAGE FUNDAMENTAL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONNERS PARENT RATING SCALE; CONNERS TEACHER RATING SCALE; DISEASE ASSOCIATION; DISEASE MODEL; FRAGILE X SYNDROME; GABAERGIC SYSTEM; HUMAN; INTELLIGENCE QUOTIENT; KIDDIE SCHEDULE FOR AFFECTIVE DISORDER AND SCHIZOPHRENIA SCALE; NERVE CELL PLASTICITY; NEUROANATOMY; NONHUMAN; OUTCOME ASSESSMENT; PEABODY PICTURE VOCABULARY TEST; PHENOTYPE; PROTEIN TARGETING; RATING SCALE; REPEATABLE BATTERY FOR ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; REPETITIVE BEHAVIOR SCALE; REVIEW; SIGNAL TRANSDUCTION; SOCIAL RESPONSIVE SCALE; SWANSON NOLAN PELHAM QUESTIONNAIRE PARENT RATING SCALE; TREATMENT INDICATION; VINELAND ADAPTIVE BEHAVIOR SCALE; VISUAL ANALOG SCALE; ANIMAL; BIOLOGICAL MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MICE, KNOCKOUT; MODELS, NEUROLOGICAL; MOLECULAR TARGETED THERAPY; NEURONAL PLASTICITY; NEURONS; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84909595431     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.10.012     Document Type: Review

References (168)

1. Aman M.G., Burrow W.H., Wolford P.L. The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes. Am. J. Ment. Retard. 1995, 100:283-292.
2. Antar L.N., Li C., Zhang H., Carroll R.C., Bassell G.J. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol. Cell. Neurosci. 2006, 32:37-48.
3. Bagni C., Tassone F., Neri G., Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J. Clin. Invest. 2012, 122:4314-4322.
4. Bakker C.E., Oostra B.A. Understanding fragile X syndrome: insights from animal models. Cytogenet. Genome Res. 2003, 100:111-123.
5. Bakker C.E., Verheij C., Willemsen R., Vanderhelm R., Oerlemans F., Vermey M., Bygrave A., Hoogeveen A.T., Oostra B.A., Reyniers E., Deboulle K., Dhooge R., Cras P., Van Velzen D., Nagels G., Martin J.J., Dedeyn P.P., Darby J.K., Willems P.J. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78:23-33.
6. Bar-Nur O., Caspi I., Benvenisty N. Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J. Mol. Cell Biol. 2012, 4:180-183.
7. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
8. Berry-Kravis E., Krause S.E., Block S.S., Guter S., Wuu J., Leurgans S., Decle P., Potanos K., Cook E., Salt J., Maino D., Weinberg D., Lara R., Jardini T., Cogswell J., Johnson S.A., Hagerman R. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: acontrolled trial. J. Child Adolesc. Psychopharmacol. 2006, 16:525-540.
9. Berry-Kravis E., Sumis A., Hervey C., Nelson M., Porges S.W., Weng N., Weiler I.J., Greenough W.T. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 2008, 29:293-302.
10. Berry-Kravis E.M., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., Hutchison J., Snape M., Tranfaglia M., Nguyen D.V., Hagerman R. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009, 46:266-271.
11. Berry-Kravis E.M., Hessl D., Rathmell B., Zarevics P., Cherubini M., Walton-Bowen K., Mu Y., Nguyen D.V., Gonzalez-Heydrich J., Wang P.P., Carpenter R.L., Bear M.F., Hagerman R.J. Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 2012, 4:152ra127.
12. Bilousova T., Dansie L., Ngo M., Aye J., Charles J.R., Ethell D.W., Ethell I.M. Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse model. J. Med. Genet. 2008, 46:94-102.
13. Bishu S., Schmidt K.C., Burlin T., Channing M., Conant S., Huang T., Liu Z.H., Qin M., Unterman A., Xia Z., Zametkin A., Herscovitch P., Smith C.B. Regional rates of cerebral protein synthesis measured with L-[1-11C]leucine and PET in conscious, young adult men: normal values, variability, and reproducibility. J. Cereb. Blood Flow Metab. 2008, 28:1502-1513.
14. Bishu S., Schmidt K.C., Burlin T.V., Channing M.A., Horowitz L., Huang T., Liu Z.H., Qin M., Vuong B.K., Unterman A.J., Xia Z., Zametkin A., Herscovitch P., Quezado Z., Smith C.B. Propofol anesthesia does not alter regional rates of cerebral protein synthesis measured with L-[1-(11)C]leucine and PET in healthy male subjects. J. Cereb. Blood Flow Metab. 2009, 29:1035-1047.
15. Bodfish J.W., Symons F.J., Parker D.E., Lewis M.H. Varieties of repetitive behavior in autism: comparisons to mental retardation. J. Autism Dev. Disord. 2000, 30:237-243.
16. Braun K., Segal M. FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb. Cortex 2000, 10:1045-1052.
17. Busner J., Targum S.D. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007, 4:28-37.
18. Bussing R., Fernandez M., Harwood M., Wei H., Garvan C.W., Eyberg S.M., Swanson J.M. Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample. Assessment 2008, 15:317-328.
19. Centonze D., Rossi S., Mercaldo V., Napoli I., Ciotti M.T., Chiara V.D., Musella A., Prosperetti C., Calabresi P., Bernardi G., Bagni C. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol. Psychiatry 2007, 63:963-973.
20. Chambers W.J., Puig-Antich J., Hirsch M., Paez P., Ambrosini P.J., Tabrizi M.A., Davies M. The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch. Gen. Psychiatry 1985, 42:696-702.
21. Chang S., Bray S.M., Li Z., Zarnescu D.C., He C., Jin P., Warren S.T. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 2008, 4:256-263.
22. Chen L., Toth M. Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 2001, 103:1043-1050.
23. Choi C.H., Schoenfeld B.P., Bell A.J., Hinchey P., Kollaros M., Gertner M.J., Woo N.H., Tranfaglia M.R., Bear M.F., Zukin R.S., McDonald T.V., Jongens T.A., McBride S.M. Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res. 2011, 1380:106-119.
24. Constantino J.N., Davis S.A., Todd R.D., Schindler M.K., Gross M.M., Brophy S.L., Metzger L.M., Shoushtari C.S., Splinter R., Reich W. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J. Autism Dev. Disord. 2003, 33:427-433.
25. Curia G., Papouin T., Seguela P., Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb. Cortex 2009, 19:1515-1520.
26. D'Antuono M., Merlo D., Avoli M. Involvement of cholinergic and gabaergic systems in the fragile X knockout mice. Neuroscience 2003, 119:9-13.
27. D'Hooge R., Nagels G., Franck F., Bakker C.E., Reyniers E., Storm K., Kooy R.F., Oostra B.A., Willems P.J., Dedeyn P.P. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 1997, 76:367-376.
28. D'Hulst C., De Geest N., Reeve S.P., Van Dam D., De Deyn P.P., Hassan B.A., Kooy R.F. Decreased expression of the GABA(A) receptor in fragile X syndrome. Brain Res. 2006, 1121:238-245.
29. D'Hulst C., Heulens I., Brouwer J.R., Willemsen R., De Geest N., Reeve S.P., De Deyn P.P., Hassan B.A., Kooy R.F. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009, 1253:176-183.
30. Dansie L.E., Phommahaxay K., Okusanya A.G., Uwadia J., Huang M., Rotschafer S.E., Razak K.A., Ethell D.W., Ethell I.M. Long-lasting effects of minocycline on behavior in young but not adult fragile X mice. Neuroscience 2013, 246:186-198.
31. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., Licatalosi D.D., Richter J.D., Darnell R.B. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
32. De Vrij F.M.S., Levenga J., Van der Linde H.C., Koekkoek S.K., De Zeeuw C.I., Nelson D.L., Oostra B.A., Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in FMR1 KO mice. Neurobiol. Dis. 2008, 31:127-132.
33. Deb S., Dhaliwal A.J., Roy M. The usefulness of Conners' Rating Scales-Revised in screening for attention deficit hyperactivity disorder in children with intellectual disabilities and borderline intelligence. J. Intellect. Disabil. Res. 2008, 52:950-965.
34. den Broeder M.J., van der Linde H., Brouwer J.R., Oostra B.A., Willemsen R., Ketting R.F. Generation and characterization of FMR1 knockout zebrafish. PLoS ONE 2009, 4:e7910.
35. Dhami G.K., Ferguson S.S. Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol. Ther. 2006, 111:260-271.
36. Dictenberg J.B., Swanger S.A., Antar L.N., Singer R.H., Bassell G.J. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 2008, 14:926-939.
37. Dockendorff T.C., Su H.S., McBride S.M.J., Yang Z., Choi C.H., Siwicki K.K., Sehgal A., Jongens T.A. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 2002, 34:973-984.
38. Dolan B.M., Duron S.G., Campbell D.A., Vollrath B., Rao B.S., Ko H.Y., Lin G.G., Govindarajan A., Choi S.Y., Tonegawa S. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5671-5676.
39. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., Bear M.F. Correction of fragile X syndrome in mice. Neuron 2007, 56:955-962.
40. Dziembowska M., Pretto D.I., Janusz A., Kaczmarek L., Leigh M.J., Gabriel N., Durbin-Johnson B., Hagerman R.J., Tassone F. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am. J. Med. Genet. A 2013, 161A:1897-1903.
41. El Idrissi A., Ding X.H., Scalia J., Trenkner E., Brown W.T., Dobkin C. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci. Lett. 2005, 377:141-146.
42. Erickson C.A., Weng N., Weiler I.J., Greenough W.T., Stigler K.A., Wink L.K., McDougle C.J. Open-label riluzole in fragile X syndrome. Brain Res. 2011, 1380:264-270.
43. Erickson C.A., Wink L.K., Ray B., Early M.C., Stiegelmeyer E., Mathieu-Frasier L., Patrick V., Lahiri D.K., McDougle C.J. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013, 228:75-84.
44. Erickson C.A., Mullett J.E., McDougle C.J. Open-label memantine in fragile X syndrome. J. Autism. Dev. Disord. 2009, 39:1629-1635.
45. Errijgers V., Kooy R.F. Genetic modifiers in mice: the example of the fragile X mouse model. Cytogenet. Genome Res. 2004, 105:448-454.
46. Fatemi S.H., Folsom T.D. Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of subjects with autism: a postmortem brain study. Mol. Autism 2011, 2:6.
47. Feng Y., Gutekunst C.A., Eberhart D.E., Yi H., Warren S.T., Hersch S.M. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J. Neurosci. 1997, 17:1539-1547.
48. Frankland P.W., Wang Y., Rosner B., Shimizu T., Balleine B.W., Dykens E.M., Ornitz E.M., Silva A.J. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol. Psychiatry 2004, 9:417-425.
49. Gallagher A., Hallahan B. Fragile X-associated disorders: a clinical overview. J. Neurol. 2011, 259:401-413.
50. Gantois I., Pop A.S., de Esch C.E., Buijsen R.A., Pooters T., Gomez-Mancilla B., Gasparini F., Oostra B.A., D'Hooge R., Willemsen R. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav. Brain Res. 2013, 239:72-79.
51. Garber K.B., Visootsak J., Warren S.T. Fragile X syndrome. Eur. J. Hum. Genet. 2008, 16:666-672.
52. Gatto C.L., Broadie K. Temporal requirements of the fragile X mental retardation protein in the regulation of synaptic structure. Development 2008, 135:2637-2648.
53. Giuffrida R., Musumeci S., D'Antoni S., Bonaccorso C.M., Giuffrida-Stella A.M., Oostra B.A., Catania M.V. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J. Neurosci. 2005, 25:8908-8916.
54. Goebel-Goody S.M., Wilson-Wallis E.D., Royston S., Tagliatela S.M., Naegele J.R., Lombroso P.J. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav 2012, 11:586-600.
55. Gothelf D., Furfaro J.A., Hoeft F., Eckert M.A., Hall S.S., O'Hara R., Erba H.W., Ringel J., Hayashi K.M., Patnaik S., Golianu B., Kraemer H.C., Thompson P.M., Piven J., Reiss A.L. Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Ann. Neurol. 2007, 63:40-51.
56. Greco C.M., Navarro C.S., Hunsaker M.R., Maezawa I., Shuler J.F., Tassone F., Delany M., Au J.W., Berman R.F., Jin L.W., Schumann C., Hagerman P.J., Hagerman R.J. Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Mol. Autism 2011, 2:2.
57. Gross C., Bassell G.J. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol. Med. 2012, 18:336-345.
58. Gross C., Berry-Kravis E.M., Bassell G.J. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 2012, 37:178-195.
59. Gross C., Nakamoto M., Yao X., Chan C.B., Yim S.Y., Ye K., Warren S.T., Bassell G.J. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile x syndrome. J. Neurosci. 2010, 30:10624-10638.
60. Hazlett E.A., Buchsbaum M.S., Haznedar M.M., Singer M.B., Germans M.K., Schnur D.B., Jimenez E.A., Buchsbaum B.R., Troyer B.T. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 1998, 35:186-198.
61. Henderson C., Wijetunge L., Kinoshita M.N., Shumway M., Hammond R.S., Postma F.R., Brynczka C., Rush R., Thomas A., Paylor R., Warren S.T., Vanderklish P.W., Kind P.C., Carpenter R.L., Bear M.F., Healy A.M. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci. Transl. Med. 2012, 4:152ra128.
62. Hessl D., Berry-Kravis E., Cordeiro L., Yuhas J., Ornitz E.M., Campbell A., Chruscinski E., Hervey C., Long J.M., Hagerman R.J. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, 150B:545-553.
63. Hessl D., Rivera S.M., Reiss A.L. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2004, 10:17-24.
64. Heulens I., D'Hulst C., Van Dam D., De Deyn P.P., Kooy R.F. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav. Brain Res. 2012, 229:244-249.
65. Heulens I., Suttie M., Postnov A., De Clerck N., Perrotta C.S., Mattina T., Faravelli F., Forzano F., Kooy R.F., Hammond P. Craniofacial characteristics of fragile X syndrome in mouse and man. Eur. J. Hum. Genet. 2013, 21:816-823.
66. Hinton V.J., Brown W.T., Wisniewski K., Rudelli R.D. Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet. 1991, 41:289-294.
67. Hoeffer C.A., Sanchez E., Hagerman R.J., Mu Y., Nguyen D.V., Wong H., Whelan A.M., Zukin R.S., Klann E., Tassone F. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 2012, 11:332-341.
68. Hoeft F., Hernandez A., Parthasarathy S., Watson C.L., Hall S.S., Reiss A.L. Fronto-striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome. Hum. Brain Mapp. 2007, 28:543-554.
69. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7746-7750.
70. Huber K.M., Roder J.C., Bear M.F. Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. J. Neurophysiol. 2001, 86:321-325.
71. Irwin S.A., Galvez R., Greenough W.T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 2000, 10:1038-1044.
72. Irwin S.A., Patel B., Idupulapati M., Harris J.B., Crisostomo R.A., Larsen B.P., Kooy F., Willems P.J., Cras P., Kozlowski P.B., Swain R.A., Weiler I.J., Greenough W.T. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet. 2001, 98:161-167.
73. Isaacson J.S., Hille B. GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron 1997, 18:143-152.
74. Jacquemont S., Curie A., des Portes V., Torrioli M.G., Berry-Kravis E., Hagerman R.J., Ramos F.J., Cornish K., He Y., Paulding C., Neri G., Chen F., Hadjikhani N., Martinet D., Meyer J., Beckmann J.S., Delange K., Brun A., Bussy G., Gasparini F., Hilse T., Floesser A., Branson J., Bilbe G., Johns D., Gomez-Mancilla B. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 2011, 3:64ra61.
75. Jung K.M., Sepers M., Henstridge C.M., Lassalle O., Neuhofer D., Martin H., Ginger M., Frick A., Dipatrizio N.V., Mackie K., Katona I., Piomelli D., Manzoni O.J. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat. Commun. 2012, 3:1080.
76. Kanellopoulos A.K., Semelidou O., Kotini A.G., Anezaki M., Skoulakis E.M. Learning and memory deficits consequent to reduction of the fragile x mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila. J. Neurosci. 2012, 32:13111-13124.
77. Karumbayaram S., Novitch B.G., Patterson M., Umbach J.A., Richter L., Lindgren A., Conway A.E., Clark A.T., Goldman S.A., Plath K., Wiedau-Pazos M., Kornblum H.I., Lowry W.E. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009, 27:806-811.
78. Kaufmann W.E., Moser H.W. Dendritic anomalies in disorders associated with mental retardation. Cereb. Cortex 2000, 10:981-991.
79. Kesler S.R., Lightbody A.A., Reiss A.L. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary (1)H MRS study. Am. J. Med. Genet. A 2009, 149A:403-407.
80. Kim S.Y., Burris J., Bassal F., Koldewyn K., Chattarji S., Tassone F., Hessl D., Rivera S.M. Fear-Specific Amygdala Function in Children and Adolescents on the Fragile X Spectrum: A Dosage Response of the FMR1 Gene. Cereb. Cortex 2013, 10.1093/cercor/bhs341.
81. Koekkoek S.K., Yamaguchi K., Milojkovic B.A., Dortland B.R., Ruigrok T.J., Maex R., De Graaf W., Smit A.E., Vanderwerf F., Bakker C.E., Willemsen R., Ikeda T., Kakizawa S., Onodera K., Nelson D.L., Mientjes E., Joosten M., De Schutter E., Oostra B.A., Ito M., De Zeeuw C.I. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 2005, 47:339-352.
82. Kooy R.F. Of mice and the fragile X syndrome. Trends Genet. 2003, 19:148-154.
83. Krueger D.D., Osterweil E.K., Chen S.P., Tye L.D., Bear M.F. Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2587-2592.
84. Kwan K.Y., Lam M.M., Johnson M.B., Dube U., Shim S., Rasin M.R., Sousa A.M., Fertuzinhos S., Chen J.G., Arellano J.I., Chan D.W., Pletikos M., Vasung L., Rowitch D.H., Huang E.J., Schwartz M.L., Willemsen R., Oostra B.A., Rakic P., Heffer M., Kostovic I., Judas M., Sestan N. Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell 2012, 149:899-911.
85. Laggerbauer B., Ostareck D., Keidel E.M., Ostareck-Lederer A., Fischer U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 2001, 10:329-338.
86. Leigh M.J., Nguyen D.V., Mu Y., Winarni T.I., Schneider A., Chechi T., Polussa J., Doucet P., Tassone F., Rivera S.M., Hessl D., Hagerman R.J. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J. Dev. Behav. Pediatr. 2013, 34:147-155.
87. Lemonnier E., Robin G., Degrez C., Tyzio R., Grandgeorge M., Ben-Ari Y. Treating Fragile X syndrome with the diuretic bumetanide: a case report. Acta Paediatr. 2013, 102:e288-e290.
88. Levenga J., Hayashi S., de Vrij F.M., Koekkoek S.K., van der Linde H.C., Nieuwenhuizen I., Song C., Buijsen R.A., Pop A.S., GomezMancilla B., Nelson D.L., Willemsen R., Gasparini F., Oostra B.A. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 2011, 42:311-317.
89. Li Z., Zhang Y., Ku L., Wilkinson K.D., Warren S.T., Feng Y. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 2001, 29:2276-2283.
90. Liu Z.H., Chuang D.M., Smith C.B. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int. J. Neuropsychopharmacol. 2010, 1-13.
91. Lohith T.G., Osterweil E.K., Fujita M., Jenko K.J., Bear M.F., Innis R.B. Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. Mol. Autism 2013, 4:15.
92. Lord C., Rutter M., Goode S., Heemsbergen J., Jordan H., Mawhood L., Schopler E. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J. Autism Dev. Disord. 1989, 19:185-212.
93. Lubs H.A. A marker X-chromosome. Am. J. Hum. Genet. 1969, 21:231-244.
94. Maes B., Fryns J.P., Ghesquiere P., Borghgraef M. Phenotypic checklist to screen for fragile X syndrome in people with mental retardation. Ment. Retard. 2000, 38:207-215.
95. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
96. Martin J.P., Bell J. A pedigree of mental defect showing sex-linkage. J. Neurol. Psychiatry 1943, 6:154-157.
97. McCormack H.M., Horne D.J., Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol. Med. 1988, 18:1007-1019.
98. Menon V., Leroux J., White C.D., Reiss A.L. Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3615-3620.
99. Mesibov G.B., Schopler E., Schaffer B., Michal N. Use of the childhood autism rating scale with autistic adolescents and adults. J. Am. Acad. Child Adolesc. Psychiatry 1989, 28:538-541.
100. Michalon A., Sidorov M., Ballard T.M., Ozmen L., Spooren W., Wettstein J.G., Jaeschke G., Bear M.F., Lindemann L. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012, 74:49-56.
101. Mientjes E.J., Nieuwenhuizen I., Kirkpatrick L., Zu T., Hoogeveen-Westerveld M., Severijnen L., Rife M., Willemsen R., Nelson D.L., Oostra B.A. The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol. Dis. 2006, 21:549-555.
102. Min W.W., Yuskaitis C.J., Yan Q., Sikorski C., Chen S., Jope R.S., Bauchwitz R.P. Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 2009, 56:463-472.
103. Muddashetty R.S., Kelic S., Gross C., Xu M., Bassell G.J. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J. Neurosci. 2007, 27:5338-5348.
104. Muma J.R. Semel and Wiig's CELF: construct validity?. J. Speech Hear. Disord. 1984, 49:101-104.
105. Musumeci S.A., Bosco P., Calabrese G., Bakker C., De Sarro G.B., Elia M., Ferri R., Oostra B.A. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 2000, 41:19-23.
106. Naglieri J.A., Pfeiffer S.I. Stability, concurrent and predictive validity of the PPVT-R. J. Clin. Psychol. 1983, 39:965-967.
107. Nakamoto M., Nalavadi V., Epstein M.P., Narayanan U., Bassell G.J., Warren S.T. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15537-15542.
108. Ng M.C., Yang Y.L., Lu K.T. Behavioral and synaptic circuit features in a zebrafish model of fragile x syndrome. PLoS ONE 2013, 8:e51456.
109. Olmos-Serrano J.L., Paluszkiewicz S.M., Martin B.S., Kaufmann W.E., Corbin J.G., Huntsman M.M. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile x syndrome. J. Neurosci. 2010, 30:9929-9938.
110. Osterweil E.K., Chuang S.C., Chubykin A.A., Sidorov M., Bianchi R., Wong R.K., Bear M.F. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile x syndrome. Neuron 2013, 77:243-250.
111. Osterweil E.K., Krueger D.D., Reinhold K., Bear M.F. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 2010, 30:15616-15627.
112. Pacey L.K., Heximer S.P., Hampson D.R. Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol. Pharmacol. 2009, 76:18-24.
113. Pacey L.K., Tharmalingam S., Hampson D.R. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J. Pharmacol. Exp. Ther. 2011, 338:897-905.
114. Pan L., Zhang Y.Q., Woodruff E., Broadie K. The Drosophila fragile x gene negatively regulates neuronal elaboration and synaptic differentiation. Curr. Biol. 2004, 14:1863-1870.
115. Paribello C., Tao L., Folino A., Berry-Kravis E., Tranfaglia M., Ethell I.M., Ethell D.W. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010, 10:91.
116. Pietropaolo S., Guilleminot A., Martin B., D'Amato F.R., Crusio W.E. Genetic-background modulation of core and variable autistic-like symptoms in FMR1 knock-out mice. PLoS ONE 2011, 6:e17073.
117. Portera-Cailliau C. Which comes first in fragile X syndrome, dendritic spine dysgenesis or defects in circuit plasticity?. Neuroscientist 2011, 18:28-44.
118. Price D.R., Herbert D.A., Walsh M.L., Law J.G. Study of WAIS-R Quick Test and PPVT IQS for neuropsychiatric patients. Percept. Mot. Skills 1990, 70:1320-1322.
119. Purpura R.P. Dendritic spine dysgenesis and mental retardation. Science 1974, 186:1126-1128.
120. Qin M., Schmidt K.C., Zametkin A.J., Bishu S., Horowitz L.M., Burlin T.V., Xia Z., Huang T., Quezado Z.M., Smith C.B. Altered cerebral protein synthesis in fragile X syndrome: studies in human subjects and knockout mice. J. Cereb. Blood Flow Metab. 2013, 33:499-507.
121. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20:310-319.
122. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J., Memantine Study G. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348:1333-1341.
123. Reiss A.L., Abrams M.T., Greenlaw R., Freund L., Denckla M.B. Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat. Med. 1995, 1:159-167.
124. Restrepo M.A., Schwanenflugel P.J., Blake J., Neuharth-Pritchett S., Cramer S.E., Ruston H.P. Performance on the PPVT-III and the EVT: applicability of the measures with African American and European American preschool children. Lang. Speech Hear Serv. Sch. 2006, 37:17-27.
125. Richter J.D., Klann E. Making synaptic plasticity and memory last: mechanisms of translational regulation. Genes Dev. 2009, 23:1-11.
126. Rudelli R.D., Brown W.T., Wisniewski K., Jenkins E.C., Laure-Kamionowska M., Connell F., Wisniewski H.M. Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol. 1985, 67:289-295.
127. Sansone S.M., Widaman K.F., Hall S.S., Reiss A.L., Lightbody A., Kaufmann W.E., Berry-Kravis E., Lachiewicz A., Brown E.C., Hessl D. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J. Autism Dev. Disord. 2012, 42:1377-1392.
128. Sahu J.K., Gulati S., Sapra S., Arya R., Chauhan S., Chowdhury M.R., Gupta N., Kabra M., Gupta Y.K., Dwivedi S.N., Kalra V. Effectiveness and safety of donepezil in boys with fragile X syndrome: a double-blind, randomized, controlled pilot study. J. Child. Neurol. 2013, 28:570-575.
129. Scahill L., McDougle C.J., Williams S.K., Dimitropoulos A., Aman M.G., McCracken J.T., Tierney E., Arnold L.E., Cronin P., Grados M., Ghuman J., Koenig K., Lam K.S., McGough J., Posey D.J., Ritz L., Swiezy N.B., Vitiello B., Research Units on Pediatric Psychopharmacology Autism N. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry 2006, 45:1114-1123.
130. Schapiro M.B., Murphy D.G.M., Hagerman R.J., Azari N.P., Alexander G.E., Miezejeski C.M., Hinton V.J., Horwitz B., Haxby J.V., Kumar A., White B., Grady C.L. Adult fragile X syndrome: neuropsychology, brain anatomy, and metabolism. Am. J. Med. Genet. 1995, 60:480-493.
131. Schutt J., Falley K., Richter D., Kreienkamp H.J., Kindler S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J. Biol. Chem. 2009, 284:25479-25487.
132. Sharma A., Hoeffer C.A., Takayasu Y., Miyawaki T., McBride S.M., Klann E., Zukin R.S. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 2010, 30:694-702.
133. Sheridan S.D., Theriault K.M., Reis S.A., Zhou F., Madison J.M., Daheron L., Loring J.F., Haggarty S.J. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile x syndrome. PLoS ONE 2011, 6:e26203.
134. Smit A.E., van der Geest J.N., Vellema M., Koekkoek B., Willemsen R., Govaerts L.C., Oostra B.A., De Zeeuw C.I., Vanderwerf F. Savings and extinction of conditioned eyeblink responses in fragile X syndrome. Genes Brain Behav. 2008, 7:770-777.
135. Sohn J.W., Lee D., Cho H., Lim W., Shin H.S., Lee S.H., Ho W.K. Receptor-specific inhibition of GABAB-activated K+ currents by muscarinic and metabotropic glutamate receptors in immature rat hippocampus. J. Physiol. 2007, 580:411-422.
136. Sparrow S.S., Cicchetti D.V. Diagnostic uses of the Vineland Adaptive Behavior Scales. J. Pediatr. Psychol. 1985, 10:215-225.
137. Spencer C.M., Alekseyenko O., Hamilton S.M., Thomas A.M., Serysheva E., Yuva-Paylor L.A., Paylor R. Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res 2011, 4:40-56.
138. Spencer C.M., Alekseyenko O., Serysheva E., Yuva-Paylor L.A., Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 2005, 4:420-430.
139. Su T., Fan H.X., Jiang T., Sun W.W., Den W.Y., Gao M.M., Chen S.Q., Zhao Q.H., Yi Y.H. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology (Berl) 2010, 215:291-300.
140. Sutherland G.R. Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 1977, 197:265-266.
141. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
142. Till S.M., Wijetunge L.S., Seidel V.G., Harlow E., Wright A.K., Bagni C., Contractor A., Gillingwater T.H., Kind P.C. Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome. Hum. Mol. Genet. 2012, 21:2143-2156.
143. Torrioli M., Vernacotola S., Setini C., Bevilacqua F., Martinelli D., Snape M., Hutchison J.A., Di Raimo F.R., Tabolacci E., Neri G. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am. J. Med. Genet. A 2010, 152A:1420-1427.
144. Tranfaglia M.R. The psychiatric presentation of fragile X: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev. Neurosci. 2011, 33:337-348.
145. Tucker B., Richards R., Lardelli M. Expression of three zebrafish orthologs of human FMR1-related genes and their phylogenetic relationships. Dev. Genes Evol. 2004, 214:567-574.
146. Tucker B., Richards R.I., Lardelli M. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum. Mol. Genet. 2006, 15:3446-3458.
147. Urbach A., Bar-Nur O., Daley G.Q., Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010, 6:407-411.
148. Utari A., Chonchaiya W., Rivera S.M., Schneider A., Hagerman R.J., Faradz S.M., Ethell I.M., Nguyen D.V. Side effects of minocycline treatment in patients with fragile x syndrome and exploration of outcome measures. Am. J. Intellect. Dev. Disabil. 2010, 115:433-443.
149. van't Padje S., Engels B., Blonden L., Severijnen L.A., Verheijen F., Oostra B.A., Willemsen R. Characterisation of Fmrp in zebrafish: evolutionary dynamics of the fmr1 gene. Dev. Genes Evol. 2005, 215:198-206.
150. Veeraragavan S., Bui N., Perkins J.R., Yuva-Paylor L.A., Carpenter R.L., Paylor R. Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome. Psychopharmacology (Berl) 2011, 217:143-151.
151. Veeraragavan S., Bui N., Perkins J.R., Yuva-Paylor L.A., Paylor R. The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide. Behav. Neurosci. 2011, 125:783-790.
152. Veeraragavan S., Graham D., Bui N., Yuva-Paylor L.A., Wess J., Paylor R. Genetic reduction of muscarinic M(4) receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS). Behav. Brain Res. 2011, 223:310-321.
153. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., Eussen B.E., Van Ommen G.J.B., Blonden L.A.J., Riggins G.J., Chastain J.L., Kunst C.B., Galjaard H., Caskey C.T., Nelson D.L., Oostra B.A., Warren S.T. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
154. Wang H., Kim S.S., Zhuo M. Roles of FMRP in dopaminergic stimulation induced synapse-associated protein synthesis and subsequent AMPA receptor internalization. J. Biol. Chem. 2010, 285:21888-21901.
155. Wang L.W., Berry-Kravis E., Hagerman R.J. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010, 7:264-274.
156. Wang X., Snape M., Klann E., Stone J.G., Singh A., Petersen R.B., Castellani R.J., Casadesus G., Smith M.A., Zhu X. Activation of the ERK pathway contributes to the behavioral deficit of fragile X-syndrome. J. Neurochem. 2012, 121:672-679.
157. Wang X., Snape M., Klann E., Stone J.G., Singh A., Petersen R.B., Castellani R.J., Casadesus G., Smith M.A., Zhu X. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J. Neurochem. 2012, 121:672-679.
158. Wei H., Dobkin C., Sheikh A.M., Malik M., Brown W.T., Li X. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS ONE 2012, 7:e36981.
159. Weiler I.J., Irwin S.A., Klintsova A.Y., Spencer C.M., Brazelton A.D., Miyashiro K., Comery T.A., Patel B., Eberwine J., Greenough W.T. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5395-5400.
160. Weng N., Weiler I.J., Sumis A., Berry-Kravis E., Greenough W.T. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2008, 147B:1253-1257.
161. Willemsen R., Bontekoe C., Tamanini F., Galjaard H., Hoogeveen A.T., Oostra B.A. Association of FMRP with ribosomal precursor particles in the nucleolus. Biochem. Biophys. Res. Commun. 1996, 225:27-33.
162. Willemsen R., Bontekoe C.J., Severijnen L.A., Oostra B.A. Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum. Genet. 2002, 110:601-605.
163. Yuskaitis C.J., Mines M.A., King M.K., Sweatt J.D., Miller C.A., Jope R.S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol. 2010, 79:632-646.
164. Zalfa F., Eleuteri B., Dickson K.S., Mercaldo V., De Rubeis S., di Penta A., Tabolacci E., Chiurazzi P., Neri G., Grant S.G., Bagni C. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat. Neurosci. 2007, 10:578-587.
165. Zang J.B., Nosyreva E.D., Spencer C.M., Volk L.J., Musunuru K., Zhong R., Stone E.F., Yuva-Paylor L.A., Huber K.M., Paylor R., Darnell J.C., Darnell R.B. A mouse model of the human fragile X syndrome I304N mutation. PLoS Genet. 2009, 5:e1000758.
166. Zeng H., Guo M., Martins-Taylor K., Wang X., Zhang Z., Park J.W., Zhan S., Kronenberg M.S., Lichtler A., Liu H.X., Chen F.P., Yue L., Li X.J., Xu R.H. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS ONE 2010, 5:e11853.
167. Zhang Y.Q., Bailey A.M., Matthies H.J., Renden R.B., Smith M.A., Speese S.D., Rubin G.M., Broadie K. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 2001, 107:591-603.
168. Zhang S., Faries D.E., Vowles M., Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int. J. Methods Psychiatr. Res. 2005, 14:186-201.